PTO/SB/64/PCT (04-04) Approved for use 03/31/2007.0 MB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.1		
First Named Inventor: Leah D. Fletcher		
	lication No.: To Be	
Filed: November 25, 2002 (if known	Assigned	
Title: Alloiococcus Otitidis Open Reading Frames (ORFs) Enco Antigens, Immunogenic Compositions and Uses Thereof Attention: PCT Legal Staff Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	ding Polypeptide	
The above-identified application became abandoned as to the United States because required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 3 1.495(b) or (c) as applicable. The date of abandonment is the day after the date on requirements were due. See 37 CFR 1.494(g) or 1.495(h).	7 CFR 1.494(b) or (c) or	
APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICA	CATION	
NOTE: A grantable petition requires the following items: (1) Petition fee (2) Proper reply (3) Terminal disclaimer with disclaimer fee which is required for all international applications having an international filing date before June 8, 1995; and (4) Statement that the entire delay was unintentional.		
1. Petition fee Small entity- fee \$(37 CFR 1.17(m)). Applicant claims small entity s See 37 CFR 1.27.	tatus.	
X Other than small entity - fee \$ 1,330.00(37 CFR 1.17(m))		
2. Proper reply	·	
A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s)) in the form of Transmittal Letter , Declaration and (identify type of reply) Power of Attorney, Sequence Listing Disk, Rule 821(f) International Search Report, IDS with references, Property is applicable browith.	: , Abstract Pg. 1019,	
X is enclosed herewith. GFREY1 00000151 011425 10501282		
1330 00 00 [Page 1 of 2]	ALLES SERVICES OF THE SERVICES	

07/16/2004 05 FC:1453

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit of the public which is to lite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to lite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to lite (and by the USPTO time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/64/PCT (04-04)
Approved for use through 03/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

3. Terminal disclaimer with disclaimer fee		
Since this international application has an international filing date on or after June 8,1995, no terminal disclaimer is required.		
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).		
 Statement. The entire delay in filing the required reply filing of a grantable petition under 37 CFR 1.137(b) was 	r from the due date for the required reply until the as unintentional.	
See attached document with details regarding unintentional delay.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
July 8, 2004	Harderat Signature	
1-845-602-3144	J. Darrell Fontenot	
Telephone Number	Typed or Printed Name	
46,705	Wyeth	
Registration Number, if applicable	Address	
	Five Giralda Farms, Madison, NJ	
	Address 07940	
Enclosures: X Response		
X Fee Payment		
Terminal Disclaimer		
X Attached sheets for det	ails regarding unintentional delay.	

Docket Number AM100780

First Named Inventor: Leah D. Fletcher

International (PCT)

Application Number: PCT/US02/36123

Filed: November 25, 2002 (PCT Filing Date)

Title: Alloiococcus Otitidis Open Reading Frames

(ORFS) Encoding Polypeptide Antigens, Immunogenic Compositions and Uses Thereof

Attention: PCT Legal Staff

BOX PCT

Commissioner for Patents

2900 Crystal Drive

Arlington, VA 22202-3513

DETAILS REGARDING UNINTENTIONAL DELAY:
ATTACHMENT TO FORM PTO/SB/64/PCT PETITION FOR REVIVAL OF AN INTERNATIONAL
APPLICATION FOR PATENT DESIGNATING THE
U.S. ABANDONED UNINTENTIONALLY UNDER
37 C.F.R. 1.137(b)

The following details are presented to demonstrate that the entire delay in filing the Petition for Revival from the due date for entry into the U.S. national stage until the filing of a grantable petition was unintentional.

On November 29, 2001, Applicants filed United States provisional patent application serial number 60/333,777 bearing the title Identification of Novel Alloiococcus Otitidis Open Reading Frames Encoding Polypeptide Antigens, Immunogenic Compositions and Uses Thereof. On November 18, 2002, Applicants filed United States provisional patent application serial number 60/426,742 bearing the title Novel Alloiococcus Otitidis Open Reading Frames (ORFs) Encoding Polypeptide Antigens, Immunogenic Compositions and Uses Thereof. On November 25, 2002, Applicants filed international patent application serial number PCT/US02/36123, designating all countries including the United States, and claimed priority from provisional applications 60/414,526 and 60/426,742. On June 24, 2003, Applicants filed a Demand to have the international application proceed via Chapter II of the PCT. Therefore, the deadline for entering the national phase in the United States was set at 30 months from the U.S. priority filing, or May 29, 2004.

On April 21, 2003, I was hired as a new patent Attorney (James Darrell Fontenot Reg. No. 46,705) by Wyeth. Applicant's assignee is Wyeth Holdings Corporation a whollyowned subsidiary of Wyeth. Coincident with my hiring, the attorney who drafted the above-cited priority applications was transferred into another department and the cases were subsequently assigned to my docket for prosecution.

It the normal practice of Applicant's assignee that its patent administrators handle filing of all National Phase applications except the National Phase United States application. The National Phase United States application is to be handled by the attorney to whom the case is assigned. this instance, I was the attorney and a new employee to whom the case was assigned. In addition, this was the first National Phase application to occur on my docket. I mistakenly believed that the patent administrators would file the U.S. Application on or before May 29, 2004 when they also filed the non-U.S. applications. I had this belief because there was a docket entry on my foreign filing docket, which specified that patent administrators would handle filing. I was unaware of the distinction made by our patent department between filing of the non-U.S. applications and the U.S. application. To reiterate, I was confused by the entry on the foreign docket and mistakenly believed that patent administrators would also file the U.S. application. Unfortunately, I was incorrect and the U.S. application was not filed when the non-U.S. applications were filed on the 30-month date.

I first became aware of the failure to file the U.S. national stage application during the week of June 17, 2004 when I received a phone call from the patent administrator Margaret Doran inquiring whether the U.S. application had been filed. I then confirmed that no application had been filed by me in the United States. It was at this point that I learned that I was supposed to file the application. I am informed and I believe that subsequently, Wyeth is taking steps to prevent inadvertent failures to file U.S. National Stage applications and to prevent future unintentional abandonments of applications.

After the phone call on June 17, 2004, I immediately began the process of preparing this Petition for Revival and the application for filing. The interim time was spent as follows:

- 1) During the period June 21-25, 2004, the declaration and power of attorney was sent out to the inventors.
- 2) During the period June 21 through July 1, 2004, the Petition for Revival and associated documents were prepared.
- 3) During the period July 2 through July 5, 2004, I was out of my office for personal business day and the July 4th holiday.

Because a U.S. national phase application based on international application PCT/US02/36123 would be treated as a post-GATT, no change in patent term would result from the late filing of this application. It is respectfully requested that this Petition to Revive be granted.

The undersigned Attorney for Applicants declares that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and such willful false statements may jeopardize the validity of the instant patent application or any patent issuing thereon.

Respectfully submitted,

July 8, 2007

James Darrell Fontenot Registration No. 47,705
Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
(845) 602-3144

Attorney for Applicants